1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Drugs In Development, 2022, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypothyroidism - Overview
- Hypothyroidism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypothyroidism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypothyroidism - Companies Involved in Therapeutics Development
- AbbVie Inc
- Diurnal Group Plc
- Kashiv BioSciences LLC
- Sention Therapeutics LLC
- Spectrix Therapeutics LLC
- Synthonics Inc
- Takeda Pharmaceutical Co Ltd
- Xeris Biopharma Holdings Inc
- Hypothyroidism - Drug Profiles
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Armour Thyroid - Drug Profile
- Product Description
- Mechanism Of Action
- levothyroxine - Drug Profile
- Product Description
- Mechanism Of Action
- liothyronine - Drug Profile
- Product Description
- Mechanism Of Action
- liothyronine sodium SR - Drug Profile
- Product Description
- Mechanism Of Action
- Modified Release Thyroid Hormone Formulation - Drug Profile
- Product Description
- Mechanism Of Action
- parathyroid hormone - Drug Profile
- Product Description
- Mechanism Of Action
- ST-1891 - Drug Profile
- Product Description
- Mechanism Of Action
- Hypothyroidism - Dormant Projects
- Hypothyroidism - Discontinued Products
- Hypothyroidism - Product Development Milestones
- Featured News & Press Releases
- Sep 01, 2021: Xeris Pharmaceuticals completes enrollment of its phase 1 study of levothyroxine (XP-8121)
- Aug 11, 2021: Xeris Pharmaceuticals announces FDA acceptance of its IND application for XeriSol Levothyroxine (XP-8121) for the treatment of hypothyroidism
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hypothyroidism, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypothyroidism - Pipeline by AbbVie Inc, 2022
- Hypothyroidism - Pipeline by Diurnal Group Plc, 2022
- Hypothyroidism - Pipeline by Kashiv BioSciences LLC, 2022
- Hypothyroidism - Pipeline by Sention Therapeutics LLC, 2022
- Hypothyroidism - Pipeline by Spectrix Therapeutics LLC, 2022
- Hypothyroidism - Pipeline by Synthonics Inc, 2022
- Hypothyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Hypothyroidism - Pipeline by Xeris Biopharma Holdings Inc, 2022
- Hypothyroidism - Dormant Projects, 2022
- Hypothyroidism - Discontinued Products, 2022
- Number of Products under Development for Hypothyroidism, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Diurnal Group Plc
- Kashiv BioSciences LLC
- Sention Therapeutics LLC
- Spectrix Therapeutics LLC
- Synthonics Inc
- Takeda Pharmaceutical Co Ltd
- Xeris Biopharma Holdings Inc
